The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol

Hanna Karakula-Juchnowicz 1,2, Joanna Rog 1*, Dariusz Juchnowicz 3, Igor Łoniewski 4,5, Karolina Skonieczna-Żydecka 4, Paweł Krukow 2, Małgorzata Futyma-Jedrzejewska 1 and Mariusz Kaczmarczyk 6

Abstract

Background: Current treatment of major depressive disorder (MDD) often does not achieve full remission of symptoms. Therefore, new forms of treatment and/or adjunct therapy are needed. Evidence has confirmed the modulation of the gut–brain–microbiota axis as a promising approach in MDD patients. The overall purpose of the SANGUT study—a 12-week, randomized, double-blind, and placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet—is to determine the effect of interventions focused on the gut-brain-microbiota axis in a group of MDD patients.

Methods: A total of 120 outpatients will be equally allocated into one of four groups: (1) probiotic supplementation+gluten-free diet group (PRO-GFD), (2) placebo supplementation+gluten-free diet group (PLA-GFD), (3) probiotic supplementation+gluten containing diet group (PRO-GD), and (4) placebo supplementation+gluten containing diet group (PLA-GD). PRO groups will receive a mixture of psychobiotics (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175), and GFD groups will follow a gluten-free diet. The intervention will last 12 weeks. The primary outcome measure is change in wellbeing, whereas the secondary outcome measures include physiological parameters.

(Continued on next page)
Background

Major depressive disorder (MDD) is a leading cause of disability around the world [1]. In European countries, the cost of mood disorders is estimated to be about €170 billion per year [2]. This is alarming, as more than 350 million people worldwide live with depression; worse yet, about 50% of major depressive disorder patients remain untreated [2]. This diagnosis is based on the symptomatology, a lack of biological markers, failure to achieve full remission, and high percentage of suicidal patients make MDD a challenge in the twenty-first century. A high recurrence rate and a large number of non-responders justify the urgent need to look for new therapeutic approaches [3]. Traditionally considered a brain-based disease, MDD is increasingly being recognized as a systemic whole-body illness [4]. The evidence for reduction in peripheral inflammation as a promising methods for depression management is still growing [5–7].

The immune system has a powerful impact on brain function and activity [8, 9]. In 1991, Smith proposed the macrophage theory of depression, where immune and inflammatory imbalances are the main factors leading to the onset or maintenance of MDD [10]. The author suggested that the intestine is a potential immune activation gate. Bidirectional signaling via the immune, endocrine, neural, and metabolic pathways occurs between the gastrointestinal (GI) tract and brain [11]. In his earlier works, Smith termed this connection the “food-gut-allergy-behavior axis” [10]. The intestines, having one of the largest surface areas interacting with the external environment, are exposed to more antigens than any other part of the body [12]. One of the proposed causes leading to macrophage activation is an abnormal immune response to food compounds in mechanisms other than classic allergy (i.e. immunoglobulin-E (IgE)-mediated food allergy). The interplay between genetic and environmental factors may lead to the disruption of gut proteins such as tight junctions (TJs) and subsequently to the loss in epithelial wall integrity and both gut and blood-brain barrier (BBB) permeability [13]. Disruption of the intercellular TJs may be the initial phenomenon related to uncontrolled molecule translocation (i.e. toxins, antigens, and bacteria) into the blood, which promotes pro-inflammatory cytokine synthesis and pro/anti-inflammatory imbalance [14].

A growing amount of evidence indicates that microbiota eubiosis may be one of the potential factors supporting gut function and proper communication between the gut and the brain [15–17]. The gut microbiota performs essential functions influencing gut wall integrity (i.e. the upregulation of mucin genes, immunoglobulin A (sIgA), and cytokine secretion, suppression of intestinal inflammation, and restoration of TJs structure [18]. Gut dysbiosis affects alterations in intestinal permeability [19, 20]. Beyond the macrophage theory of depression, microbial dysbiosis is associated with impaired epithelial barrier, bacterial translocation, decreased regulatory T cells in the gut mucosa, and has been shown to promote inflammation [21]. A quantitative and qualitative recovery within the composition of microbiota could therefore have a beneficial effect on inflammation and the regulation of transport via the gut to blood circulation [22–24].

Two meta-analyses confirmed the beneficial effect of probiotics in MDD patients [25, 26]. However, the potential mechanisms of action are obscure. The proposed effect of probiotics on mental state involves not only an improvement in gut wall integrity and inflammation suppression (including the influence of bacteria-derived metabolites on the microenvironment) [27], but also regulation of the hypothalamic-pituitary-adrenal (HPA) axis, thereby affecting the response to stress modulation [28]. Neural activation of stress circuits by microbiota could directly affect central nervous system (CNS) functioning. Activation of the HPA axis and excessive cortisol secretion are potential factors leading to disruption of gut wall integrity, macrophage activation, and the secretion of pro-inflammatory molecules, consequently maintaining the abnormality [15, 29].

Other potential factors interacting with the gut mucosa layer are food-derived compounds, especially gluten, a complex with high immunogenic properties consisting of...
albumins, globulins, glutenins, and gliadins [30, 31]. Gluten proteins have been found to regulate zonulin, occludin, and claudin, all previously reported to influence intestinal permeability for macromolecules [32, 33]. Gluten is hydrolyzed by gastrointestinal proteases; however, an abundance of proline and glutamine leads to incomplete gluten degradation [34]. Gluten peptides and other food-derived compounds can be absorbed and transported into the organs by blood circulation, and could provoke an immune-inflammatory cascade [14]. In individuals with gluten-related disorders, a gluten-free diet has high potential to decrease the severity of depression symptoms [35]. However, the results of studies examining the prevalence of the abnormal response of MDD patients to food compounds are contradictory [14, 36]. Gluten restriction could lead to a significantly lower intake of whole grains [37]. Reduced consumption of cereal products may be linked with a higher risk of heart diseases. Moreover, carbohydrates derived from wheat have been shown to stimulate the activity of Bifidobacteria in the colon and their elimination could negatively impact gut bacteria specificity [38]. To sum up, a gluten-free diet is not simply either 'pro-' or anti-inflammatory' and an immune response to potential food triggers depends on individual variability [39].

The formulation with potential beneficial psychological effects is a mixture of two psychobiotic (probiotic with mental health benefits) [40] strains: Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. A study with healthy volunteers showed that supplementation with mixture of L. helveticus R0052 and B. longum R0175 decreased anxiety and depression symptoms [41]. However, no study has examined the effect of this psychobiotic mixture on both mental and somatic health in patients suffering from MDD. As a result, there is an urgent need to determine the utility and differences in the effectiveness of a gluten-free diet and probiotic supplementation, together and separately, in the management of depression.

Methods/design

Aim and hypothesis

The main goal of the SANGUT study (a 12-week, randomized, double-blind, and placebo-controlled study) is to determine the effect of probiotic supplementation, a gluten-free diet, and their combination on the mental state, inflammatory markers, and gut permeability markers in adult patients with MDD. The primary hypothesis is that probiotic supplementation and/or a gluten-free diet will reduce the symptoms of depression, decrease levels of inflammatory markers, and favorably affect the integrity of the intestinal mucosal barrier.

Study design

The trial will be a prospective, randomized, double-blind (placebo = probiotic) controlled design that will last 12 weeks. The trial was registered in the clinicaltrials.gov registry (ClinicalTrials.gov identifier: NCT03877393).

Study population

A total of 120 adult volunteers with a diagnosis of major depressive disorder (MDD) will be recruited for this study. To be eligible in the trial, subjects must fulfill all of the inclusion criteria and none of the exclusion criteria, as stated below. The following inclusion criteria will be adopted:

1. Outpatients aged 18–60 years,
2. Written informed consent to participate in this study before any study-mandated procedure,
3. Meet the DSM-5 criteria for major depressive disorder (MDD) [42],
4. Body mass index (BMI) ≥18.5 kg/m² and ≤30 kg/m²,
5. MADRS (Montgomery-Asberg Depression Scale) total score of 20 points or more (moderate or severe depression) at screening (V0) and at baseline (V1), and
6. A willingness and motivation to follow the study protocol.

The exclusion criteria will be as follows:

1. Diagnosis of autoimmune, neurological, immunocompromised, thyroid, inflammatory bowel diseases, irritable bowel syndrome, diabetes, cancer, and/or IgE-dependent allergy;
2. Psychiatric comorbidities (except specific personality disorder) including mental retardation, organic brain dysfunction, or addiction (except nicotine and caffeine);
3. High risk of suicide in the investigator’s opinion;
4. An infection one month before the study baseline visit (V1);
5. The use of antibiotics and/or probiotics three months prior to the study;
6. Glucocorticosteroids and/or metformin treatment;
7. Dietary supplementation (except for vitamin D according to the “Vitamin D supplementation guidelines, 2018” [43]);
8. Changes in a pharmacotherapy and/or psychotherapy of MDD 2 weeks before the trial entry;
9. No specific (e.g. elimination, vegan, reduction) diet and changes in physical activity 4 weeks before the trial entry, and
10. Pregnancy or lactation.

Reasons for the participant to be discontinued from the study:

1. Withdrawal of informed consent,
(2) Lack or incomplete compliance with the diet and/or probiotic supplementation,
(3) Non-attendance at the study visits,
(4) Exclusion criteria found after enrollment, and
(5) Any serious adverse event during the intervention period (based on data safety monitoring).

Sample size calculation
Based on the results of other studies evaluating probiotic strains that will be used in the present study, we assume that the mean effect of intervention will be of a medium size. As the primary outcomes will be repeatedly measured and four groups of patients will be entering the trial, there will be an approximately 81% probability of correctly rejecting the null hypothesis of no difference between the study groups with a total of 116 patients.

Randomization
Randomization will be performed using a random sequence generator [44]. Patients will be randomized independently on antibody titers against gluten levels. The previously performed analyses will be used to check whether markers of abnormal response to gluten are useful in selecting the subgroup of patients who potentially benefit from a gluten-free diet.

Recruited individuals will be allocated into one of four groups:

1. Probiotic supplementation + gluten-free diet group (PRO-GFD; n = 30)
2. Placebo supplementation + gluten-free diet group (PLA-GFD; n = 30)
3. Probiotic supplementation + gluten-containing diet group (PRO-GD; n = 30)
4. Placebo supplementation + gluten-containing diet group (PLA-GD; n = 30)

Dietary interventions

Probiotic supplementation
The probiotic groups (PRO-GFD and PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of $3 \times 10^9$ colony forming units (CFU) per day divided into two equal doses. The probiotic preparation will contain two bacteria strains: Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The placebo groups (PLA-GFD and PLA-GD) will receive the same capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The placebo will be indistinguishable in color, smell, and taste from the probiotic formulation. Participants will be asked to consume the supplements before breakfast.

Each of the study participants will be asked to collect the blister packs to evaluate compliance after the study.

Elimination diet
The patients in the GFD groups will follow the elimination diet containing no gluten. During the Baseline Visit (V1), participants will be educated about the rules of gluten-free diet restrictions and informed that the elimination diet is not a caloric restriction diet so the consumption of nutrients should not be changed. Information on the origins of gluten, the grains containing gluten, and highly processed food with gluten, will be received by all participants. They will be encouraged to consume natural, fresh foods and read the labels of food products in order to evaluate the gluten content. To avoid potential outcome bias resulting from a balanced diet and change in dietary habits, participants will be asked to follow their usual eating patterns, excluding gluten-containing products.

Before the intervention is implemented (between V0 and V1), patients will be asked to keep a diet diary (a 3-day food record). Changes and modifications in typical food consumption (based on the 3-day food record) during the consultation (at baseline, V1) will be proposed by a dietitian. Moreover, each participant will receive a list of products to be eliminated as well as a list of substitutes with the same taste, organoleptic properties, and nutritional values. A guide on the gluten-free diet and seven proposed menus for breakfast, lunch, dinner, and snacks will be given to each participant. The diet protocol will include only qualitative data, without the portion sizes, to keep the amount of food consumed at the current level. Patients will be educated about sticking to a diet by a dietitian during a consultation (visit V1).

Data collection and methods
Tools
The following clinical/dietary information will be obtained:

1. Socio-demographic Data (a self-prepared questionnaire)
2. Dietary habits: Food Frequency Questionnaire (FFQ-6) [45], a 3-day food record
3. Physical activity: The International Physical Activity Questionnaire (IPAQ) [46]
4. Smoking status by breath carbon monoxide levels in exhaled air
5. Vital signs: Heart rate (HR), blood pressure (RR), and core body temperature
6. Anthropometric measures: Weight, height, body mass index (BMI), waist-to-hip ratio, and body composition
7. The severity of depressive symptoms: Montgomery-Asberg Depression Scale (MADRS) [47], and Beck’s Depression Inventory (BDI) [48]
(8) Psychological problems and symptoms of psychopathology: Symptom Checklist-90 Questionnaire (SCL-90) [49]

(9) Quality of life: Short Form (36) Health Survey (SF-36) [50]

(10) Gastrointestinal symptoms: Gastrointestinal Symptom Rating Scale (GSRS) [51]

(11) Subjective assessment of stress levels: Perceived Stress Scale (PSS-10) [52] and Childhood Trauma Questionnaire (CTQ) [53]

In the blood serum, we will evaluate markers of:

(1) Gut barrier integrity: Intestinal fatty acid-binding protein (IFABP/FABP2), and lipopolysaccharide binding protein (LBP)

(2) Gluten sensitivity: Immunoglobulin G and immunoglobulin A anti-gliadin antibodies (anti-AGA IgG/IgA), and IgG anti-tissue transglutaminase (anti-tTG2)

(3) Inflammation: High-sensitivity C reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-alpha), and interleukins IL-6 and IL-1 beta

(4) HPA axis activity: Cortisol

(5) Metabolic indices: Total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides (TG), glucose, and insulin

(6) Liver function: Alanine aminotransferase (ALT) and asparagine aminotransferase (AST)

(7) Excluded diseases: Hematopoietic system (peripheral blood morphology), thyroid diseases (thyroid stimulated hormone, TSH), diabetes (hemoglobin glycosylated, HbA1c), coeliac disease (total-IgA and IgG antibodies against tissue transglutaminase, anti-TG2), and allergy (total-IgE antibodies levels).

The following analyses will be conducted in the stool: gut microbiota (taxonomic and functional analysis) and concentrations of short-chain fatty acids (SCFAs).

Activity of the brain and its relationships with implemented interventions will be assessed with resting-state electroencephalography (EEG). After collecting raw EEG recordings, they will undergo mathematical analysis to obtain the quantitative parameters characterizing neural activity which can be evaluated with reference to applied experimental effects.

Methods of assessment

Dietary assessment and diet adherence

Diet assessment and adherence to the protocol will be examined using the Food Frequency Questionnaire with six answers (FFQ-6) validated on a Polish population [45]. The FFQ questionnaire will be used to assess intake of 62 products (including the main gluten sources) divided into eight groups that are consumed in Poland. Respondents will have to select one out of six frequency categories: (1) never or almost never, (2) once a month or more rarely, (3) several times a month, (4) several times a week, (5) daily, and (6) several times a day. The FFQ questionnaire will be filled out by a clinical dietitian with experience in conducting nutritional interviews. Using the “Album of photographs of food products and dishes” [54], participants will determine the serving sizes of the consumed products. The amount of food intake which is not included in the aforementioned album will be determined using the ilewazy.pl website [55]. Patients will also be asked to complete a 3-day food record (including two weekdays and one weekend day) before the Baseline Visit (V1), and twice in the study period (first between 1 and 6 weeks from the implementation of the diet, and for the second time between 6 and 12 weeks from the implementation). Based on the food records, we will be able to estimate the nutritional value and assess the intake and percentage of consumed nutrients from the recommended amounts. According to the method from earlier studies (multiplying protein contained in gluten cereal by 0.8) [56, 57], gluten in patients’ diet will be estimated from the FFQ questionnaire and 3-day food records. Based on the FFQ results, alcohol consumption will also be estimated. A possible influence of other nutritional factors (energy value, nutrient intake) on the obtained results will be checked before and during the intervention based on dietary diaries.

Other lifestyle factors

Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ) which allows for expressing physical activity in the metabolic equivalent – MET-min/week [46]. The IPAQ estimates physical activity of different intensity levels (walking, moderate-intensity, and vigorous-intensity activities) during the last seven days. Based on the results, the responders are classified into one of three activity categories: ‘insufficient,’ ‘sufficient,’ or ‘high’. The level of physical activity is a potential confounder having an impact on gut microbiota composition [58, 59] and some biochemical parameters [60, 61]. Studies have also shown that excessive workouts affect gut permeability [59].

Smoking status will be evaluated by means of the Micro+Smokerlyzer (Bedfont Scientific Ltd., Station Road, Harrietsham, Maidstone, Kent, ME17 1JA, England) which is a quick method to analyze carboxyhemoglobin and carbon monoxide parts per million (ppm) levels in exhaled air. The monitor uses an electrochemical sensor, has a concentration range of 0 to 500 ppm, repeatability of less than ±5%, and an accuracy of 2 ppm. Evidence indicates
that smoking dysregulates gut microbiome and leads to low-grade inflammation [62, 63].

**Vital signs**

Systolic and diastolic blood pressure and pulse rate will be measured using the standard digital meter in a seated position, after at least five minutes of rest, three times (in 1-min intervals) by placing the cuff on the left upper arm. The first measurement will be discarded. During the same visit, vital signs will be taken prior to blood sampling. Core body temperature will be monitored using a forehead digital thermometer. Abnormalities of clinical significance will be recorded as an adverse event.

**Anthropometric measurement**

The measurement of waist and hip circumferences (repeated twice at each visit) will be performed according to the World Health Organization (WHO) protocol [64]. Weight, body mass index (BMI), fat mass, muscle mass, and total body water will be measured using a segmental multifrequency bioimpedance analyzer (Tanita BC-601; Tanita Corp., Tokyo, Japan). All anthropometric data will be recorded after an overnight fast. Patients will be weighed while wearing light clothing and without metal objects (i.e. belt, jewelry). Participants will be asked to wear a similar amount of clothes on each visit. Evidence confirms a link between anthropometric parameters and other parameters assessed in our study [65–67]. Changes in anthropometric data will be considered as potential factors linked with metabolic parameters, inflammatory and gut permeability markers, gut microbiota composition, and physical and mental state. There is some weak evidence that gut microbiota may have an impact on body weight [68].

**Patients’ well-being**

To check the effect of the intervention on the severity of depression, other psychiatric features, co-morbid symptoms, and general patient health, the following scales and questionnaires will be used:

1. MADRS scale (Montgomery-Asberg Depression Rating Scale) [47] for clinical assessment of depression severity will be administered by a well-trained psychiatrist. The MADRS is a 10-item scale that includes questions concerning apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The assessment will always be performed by the same person blinded to the intervention type.
2. BDI (Beck’s Depression Inventory [48]) for self-reporting measurement of the severity of depression. The BDI consists of 21 multiple-choice questions.
3. SCL-90 (The Symptom Checklist-90 Questionnaire [49]) assesses the general intensity of psychopathological impairment. The SCL-90 is a self-reporting measurement tool that includes 90 items regarding the currently felt symptoms divided into nine subscales: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism.
4. PSS-10 (The Perceived Stress Scale [52]) includes 10 items and measures the self-reported perception of psychological stress in respondents by asking about their thoughts and feelings during the last month.
5. CTQ Questionnaire (Childhood Trauma Questionnaire [53]) is used for the self-assessment of traumatic experiences which covers 28 items in total and consists of five subscales addressing: physical, emotional, and sexual abuse, and physical and emotional neglect.
6. SF-36 Health Survey (The Short Form (36) Health Survey [50]) includes patients’ reports about their vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
7. The GSRS scale (The Gastrointestinal Symptoms Rating Scale [51]) is a self-administered questionnaire which assesses five symptom clusters (combined from 15 items) depicting: reflux, abdominal pain, indigestion, diarrhoea, and constipation experienced over the past week.

**EEG**

Electroencephalography (EEG) is a non-invasive method enabling the assessment of electrophysiological neural activity. Subjects participating in the study will sit with closed eyes throughout the EEG recording. The assessment will be carried out during the daytime, between 10:00 a.m. and 2:00 p.m. to ensure that participants will remain awake. The EEG recordings, after the initial calibration of the equipment, will last about 15 min so that after cleaning, we will have at least five minutes of pure electrophysiological recording available from each participant. To ensure study comparability and reproducibility of the study, a standard procedure will be conducted, with 19 electrodes placed according to the International 10–20 system [69, 70].

Oscillatory activity of the central nervous system may be analyzed in order to extract relevant information regarding the functioning of the brain. Resting-state EEG assesses spontaneous brain activity organized as a
synchronized, or in the case of brain pathology, a desynchronized, system. The evaluation of task-free neural behavior allows a qualitative, clinical assessment of parameters such as the dominant frequency, the occurrence of pathological phenomena such as seizures, or abnormal brain response to stimulation. Digitized EEG recordings can be analyzed with advanced mathematical methods to assess the functional connectivity and organization of intrinsic neural networks. Functional connectivity (FC) refers to the process of neural synchronization that functionally integrates the cortical areas necessary to maintain consistent and effective brain activity. Based on various properties of the EEG signal, e.g. phase coupling, by applying non-linear mathematical methods (e.g. phase lag index, PLI) [71], it is possible to assess changes in the synchronization patterns as an effect of a given experimental intervention as well as those that reduce the inflammatory states within an organism. The most advanced analyses of the EEG signal concern the modelling of brain activity in the form of functional neural networks [72]. Network analysis enables the reconstruction of synchronized neural behavior as a global system of inter- and intra-cortical interactions, and not only as a given set of connections. Due to the implementation of the network approach, it is also possible to distinguish cortical areas, so-called hubs, that play a key role in neural integration. Their location and strength are critically important indicators of how the brain functions as an information processing system. Considering the above, we will apply the PLI as a functional connectivity measure and the network indicators adopted from graph theory such as centrality, network assortativity, metrics indicative of path length, and small-worldness [73].

Changes in FC have also been studied in patients with MDD [74, 75] and have shown that these EEG markers may have potential value as biomarkers. This concept created a new clinical possibility of considering MDD symptoms in connection with gut microbiota and structural and functional changes in the brain.

**Sampling**

**Blood collection**

Venous blood will be collected by qualified nurses. The collection will be performed under conditions of fasting, upon overnight resting, in the morning, between 8:00 and 10:00 a.m., to minimize the effect of changes in daily cortisol production. To obtain serum, blood will be centrifuged at 1500 x g for 10 min. Until analysis, the blood samples will be preserved in 2 mL Eppendorf tubes and frozen at a temperature of – 80 °C.

**Stool collection**

Participants will be asked to collect stool samples after overnight fasting to avoid the effect of food consumption on short-chain fatty acid synthesis. Each participant will receive detailed instructions describing the method for material collection. A plastic holder will be used to collect faeces into a sterilized screw-capped collection container. Participants will be asked to store the sample in a fridge and deliver the sample up to 24 h after collection to the clinic. The samples will be preserved in 2 mL Eppendorf tubes containing 600 µL DNA/RNA later solution (Zymo Research, Freiburg, Germany) to prevent the degradation processes and will be frozen at – 80 °C until the beginning of the microbiota analyses.

DNA extracted from the stool will be amplified using primers flanking the hypervariable region of the 16S rRNA gene. 16S amplicons will be sequenced using an Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) and the raw reads will be processed using the Mothur pipeline (version 1.39.5) [76]. The SILVA 132 rRNA database [77] will be used to assign taxonomy. To predict a microbial community metagenome and its functional potential based on the 16S data, the PICRUST software package will be used [78].

An overview of the study design and assessments to be conducted during the study and their timing is presented in Fig. 1 (study design) and Table 1 (assessment point times and examined variables).

**Data management and analysis plan**

**Data analysis principles**

To evaluate the efficacy of the intervention on the well-being of patients, the following changes from the baseline (V1) to the end of the study (V3) will be determined as primary outcomes:

1. The severity of depression symptoms:
   - (a) MADRS total score
   - (b) BDI total score
2. The severity of psychopathological impairment:
   - (a) SCL-90 total score
3. The quality of life:
   - (a) SF-36 total score
4. Stress levels:
   - (a) PSS-10 total score

To evaluate the effect of the intervention on physiological parameters [79], the following changes will be determined as secondary outcomes:

1. In serum, from the screening (V0) to the end of the study (V3), levels of:
   - (a) proinflammatory biomarkers: hs-CRP, IL-6, IL-1beta, and TNF-alpha
   - (b) gluten sensitivity biomarkers: anti-TG2 IgG antibodies and anti-AGA IgG/IgA antibodies
   - (c) intestinal permeability biomarkers: I-FABP/FABP-2 and LBP
Fig. 1 Timeline of SANGUT STUDY visits. V0 – Screening visit; V1 – Baseline Visit; V2 – Visit 2; V3 – End of Study Visit

Table 1 Schedule of study procedures

| Visit Number | Visit time and Window | Screening | Randomization | Intervention Period | End of the study |
|--------------|-----------------------|-----------|---------------|---------------------|------------------|
| V0           | Day -7 to -1          | V0        | V1            | Day 0               | V2               |
| V1           | Day 0                 |           |               | 6 weeks ±3 days     | V3               |
| V2           |                       |           |               |                     |                  |
| V3           |                       |           |               |                     |                  |

- Informed consent +
- Inclusion/exclusion criteria + +
- Somatic examination + +
- Neurological examination + +
- Socio-demographic characteristics +
- Medical history +
- Psychiatric history +
- Depression symptoms severity + + + +
- Stress level + + + +
- Quality of life + + + +
- Gastrointestinal symptoms + + + +
- Dietary assessment + + + +
- Physical activity + + + +
- Anthropometric measures + + + +
- Vital measures + + + +
- Smoking status + + + +
- Blood sample + + +
- Stool sample + + +
- Electroencephalography + + +
- Adverse events report + + +

Karakula-Juchnowicz et al. Nutrition Journal (2019) 18:50 Page 8 of 13
Monitoring data collection
All study team members will be trained by qualified, well-experienced professionals in areas referring to the planned measurements for the accurate performance of the procedures, data collection, and adherence to the study. Previously established procedures for data collection will be used (see Methods of Assessment section). The quality and correctness of the data collection will be checked by a researcher completing a structured online spreadsheet after each visit. Assessment of the electronic document will be performed once a week by a supervisor.

Statistical analysis
Statistical analysis will be performed according to the E9 Statistical Principles for Clinical Trials [80]. For quantitative outcomes, the between-group comparisons will be performed using the ANOVA or Kruskal-Wallis rank-based nonparametric test depending on the data distribution followed by appropriate post-hoc tests. The qualitative outcomes will be compared using the Chi-square test. Longitudinal data will be analyzed with either repeated measures of ANOVA or aligned rank-transform ANOVA, depending on the data distribution, or McNemar’s test.

The analysis of the gut microbial community will include alpha diversity, beta diversity, ordination techniques (a principal coordinate analysis), and taxonomic and functional differences. Alpha diversity will be measured by means of the Chao1 (richness) and Shannon (richness and evenness) indices. All indices will be determined using originally observed count data (without data pre-processing) and comparison within the groups (V0–V3) and between the groups at the end of the study (at V3) using the non-parametric Wilcoxon signed-rank test or Mann-Whitney (or Kruskal-Wallis) test, respectively. Beta-diversity will be measured by means of the Bray-Curtis dissimilarity metric and the weighted UniFrac distance metric. Beta-diversity analysis will be preceded by the removal of rare species and normalization to account for unequal library sizes. The between-group differences in gut microbial composition will be visualized using principal coordinate analysis based on the Bray-Curtis dissimilarity and UniFrac distances. The permutational multivariate analysis of variance (PERMANOVA) will be conducted on the Bray-Curtis and weighted UniFrac dissimilarity matrices to assess the group-level (at V3) differences. Taxonomic differential abundance will be tested by comparing the fractional abundances. The analysis of alpha and beta diversity, ordination analysis, and taxonomic differential abundance will be conducted using the R (version 3.5.1) package Phyloseq [81]. The PERMANOVA+ add-on package of PRIMER 7 (version 7.0.13) will be used as analysis tools to compare beta diversity. To predict the metagenome functional content using the output of the 16S rRNA analysis pipeline, the software package PICRUSt will be used. Functional abundance differences will be analyzed and visualized using STAMP [82]. To account for multiple testing, FDR-adjusted p values (q values) will be reported.

Project Management
Timeline of the study
This study will consist of four visits (see Table 1 and the Methods of Assessment section for a detailed description of the framing and all procedures performed during each visit):

1. V0: Screening Visit to screen and enroll eligible patients into the study;
2. V1: Baseline Visit up to 1 week after V0 to randomize patients to one of four arms of the study;
3. V2: Visit 2, during the intervention period, after six weeks (±3 days) from Baseline Visit;
4. V3: End of Study Visit to complete all procedures in this study, after 12 weeks (±3 days) from Baseline Visit.

The total duration from the screening to the end of the study will be 13 weeks at maximum.

Data safety monitoring
Based on anthropometric measurements, vital signs, and self-reported patient symptoms recorded at the visits during the intervention period (V2 and V3), the long-term safety and tolerability of probiotics and gluten elimination will be assessed. Participants will be asked to document any suspected adverse events in written form and to report them at the next visit.

Discussion
A potential connection between abnormal immune response, food-derived compounds, and MDD is still poorly
understood; however, increasing evidence has confirmed the importance of the interplay between microbiota, gut permeability, immune-inflammatory processes in the pathophysiology of MDD [83]. The modulation of the gut-microbiota-brain axis could therefore be a promising therapeutic target for mental illnesses [15, 16, 84]. This concept has produced a new clinical approach involving dietary interventions restoring gut eubiosis in the treatment of MDD.

A gluten-free diet and probiotic supplementation, separately and in combination, have received much attention as a potential therapeutic strategy. This approach is of particular interest as it considers that a gluten-free diet changes the microbiota profile and alters the activity of microbiota-mediated biochemical pathways [85, 86]. Notably, the microbiota is able to digest gluten. Bacterial and fungal enzymes are involved in gluten breakdown and the formation of peptides with different immunogenic capacities [87, 88]. Hence, gut dysbiosis could intensify the immunogenic effect of cereal-derived compounds [89]. Studies have confirmed differences in gut microbiota of patients with celiac disease and non-celiac gluten sensitivity (NCGS) [90, 91]. Eubiosis is necessary for both appropriate gut function and restoration of intestinal barrier integrity, [87, 88, 92].

This bidirectional interaction between a GFD and microbiota suggests that the combination of a gluten-free diet and probiotic supplementation is essential for the inhibition of the immune-inflammatory cascade. However, whether the separate use of one of these interventions or their combination will be the most effective treatment strategy to regulate CNS and digestive tract functions in MDD patients has yet to be determined. Results confirming the efficacy of such a therapeutic approach would provide support for the introduction of dietary interventions as an integral part of treatment in psychiatric wards.

To the best of our knowledge, this will be the first intervention study assessing the efficacy of both probiotic supplementation and a gluten-free diet and comparing the effect of both interventions and their combination in MDD patients. The protocol and the outline were developed by a multidisciplinary researcher team. The methodology employed in the study benefited greatly from our diverse set of knowledge, experience and perspectives. Considering the highly rigorous selection criteria, the participant group is relatively large. Rigorous procedures established for this trial will be followed by well-trained researchers to ensure that research will be conducted in accordance with standards of best practice. The measurements listed above will be introduced to reduce the potential bias related to confounding variables (e.g. smoking, physical activity, and diet).

There may be some possible limitations in the design of the study:

First, the impossibility of blinding the diet is a factor that could affect assessment of both the participant and investigator. For this reason, the researcher evaluating the severity of symptoms will not be informed as to whether the patient will be allocated to the GFD or GD arm of intervention.

Second, the lack of motivation is a symptom commonly experienced by MDD patients and could contribute to the non-attendance at the study visits, incomplete implementation of the intervention, or failure to complete the intervention.

Third, patients in the GFD groups receiving dietary advice might try to introduce other changes in food consumption (e.g. reduce the food portion size and/or consume more vegetables and fruits). Therefore, health improvement may not be specific to the implemented gluten-free diet.

Finally, recall bias in self-reporting is another potential confounder of the study. However, dietary consultation and food intake assessment during the study period should minimize the likelihood of its occurrence.

Abbreviations
AGA: Anti-gliadin antibodies; ALT: Alanine aminotransferase; anti TG2: antibodies against tissue transglutaminase; AST: Aspartate aminotransferase; BBB: Blood brain barrier; BDI: Beck’s Depression Inventory; BMI: Body mass index; CNS: Central nervous system; CTQ: Childhood Trauma Questionnaire; D59-H5: Diagnostic and Statistical Manual of Mental Disorders; fifth edition; EEG: Electroencephalography; FC: Functional connectivity; FFQ: Food Frequency Questionnaire; GD: Gluten containing diet; GFD: Gluten-free diet; GI: Gastrointestinal; GSRS: Gastrointestinal Symptom Rating Scale; HbA1c: Hemoglobin glycosylated; HDL: High density lipoprotein; HPA: Hypothalamic-pituitary-adrenal; HR: Heart rate; hsCRP: high-sensitivity C reactive protein; IFABP: Intestinal fatty acid-binding protein; IgE: Immunoglobulin-E; IPAQ: International Physical Activity Questionnaire; IBD; Inflammatory bowel disease; IBDQ: Inflammatory Bowel Disease Questionnaire; IGF-1: insulin-like growth factor-1; IOM: Institute of Medicine; IP: Interleukin-1; IP: Interleukin-1; LBP: Lipopolysaccharide binding protein; LDL: Low density lipoprotein; MADRS: Montgomery-Asberg Depression Scale; MDD: Major depressive disorder; PLA: Placebo; PPM: Parts per million; PRO: Probiotic; PSS-10: Perceived Stress Scale; RR: Blood pressure; SCFA: Short chain fatty acids; SCL-90: Symptom Checklist-90 Questionnaire; SF-36: Short Form (36) Health Survey; sIgA: secretory immunoglobulin A; TG: Triglycerides; TJs: Tight junctions; TNFα: Tumor necrosis factor alpha; TSH: Thyroid stimulated hormone; V1: Baseline Visit; V1: Consultation Visit; WHO: World Health Organization

Acknowledgments
The authors gratefully acknowledge the Sanprobi Company for providing probiotics used in the trial and language service for paper editing.

Authors’ contributions
Conceptualization, HK-J, JR and DJ; methodology, HK-J, JR, DJ, IL, KS-Z, PK, MF-J and MK; writing—original draft preparation, HK-J, JR, DJ, IL, KS-Z, PK, MF-J and MK; writing—review and editing, HK-J, JR, DJ, IL, KS-Z, PK, and MK; visualization, HK-J and JR. All authors read and approved the final manuscript.

Funding
This study was supported by a research grant from the Medical University of Lublin (DS. 192/19). The probiotics will be donated by a distributor of probiotic formulas. The funding sources had no role in the study design, data collection, interpretation of analysis, writing of the manuscript, or decision to submit the publication.

Availability of data and materials
The datasets used and analyzed during the study will be available from the corresponding author on request.
Ethics approval and consent to participate
The study will be conducted in accordance with the ethical principles that have their origin in the ICH Good Clinical Practice Guidelines [90] and the Declaration of Helsinki [91]. The protocol was approved by the Ethics Committee of the Medical University of Lublin (the project identification code: KE-0254/10/2018). Patients will be informed in detail on the course of the study, all study procedures, potential risks, and the benefits of each intervention. The study outline will be given to participants in writing. The information form will contain the aim and justification for the research, statements on voluntary participation, the timeline of the study, potential risks, the manner in which the personal information will be kept confidential, and the right to withdraw from the study at any time) and without giving any reason.

Consent for publication
Not applicable.

Competing interests
IL is a foundation shareholder in Sanprobi, a probiotics distributor. KS-Z and H-KJ received remuneration from Sanprobi. However, the content of this study was not constrained by this fact. Moreover, our adherence to Nutrition Journal policies on sharing of data and materials was unaffected. The other authors declare that they have no competing interests.

Author details
1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Gruska 1, 20-439 Lublin, Poland. 2Department of Clinical Neuropsychiatry, Medical University of Lublin, 20-439 Lublin, Poland. 3Department of Psychiatric Nursing, Medical University of Lublin, 20-124 Lublin, Poland. 4Department of Biochemistry and Human Nutrition, Pomeranian Medical University, 71-460 Szczecin, Poland. 5Sanprobi sp. z o.o. sp. k, Szczecin, Poland. 6Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.

Received: 8 May 2019 Accepted: 16 August 2019
Published online: 31 August 2019

References
1. Depression in Europe: facts and figures. 2019 Cited 2019 Mar 7. Available from: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/news/news/2012/10/depression-in-europe-depression-in-europe-facts-and-figures
2. Depression in Europe. 2012 Cited 2019 Mar 7. Available from: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/news/news/2012/10/depression-in-europe-depression-in-europe-facts-and-figures
3. Maziak DA, Horberger JC, Altar CA, Degter I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;66(5):457–67.
4. Rantala MJ, Luoto S, Krams I, Karlsson H. Depression subtyping based on pregnancy and therapy of depressive disorders. Nutr Neurosci. 2017;20:110–8.
5. Karukas A, Arboleya S, Moloney RC, Peterson VL, Murphy K, Clarke G, et al. Targeting the microbiota-gut-brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol Psychiatry. 2017;82:472–87.
6. Sandhu KV, Sherwin E, Schellekens H, Stanton C, Dinan TG, Cryan JF. Feeding the microbiota-gut-brain axis: diet, microbiome, and neuro-pyschiatry. Transl Res. 2017;179:223–44.
7. Severance EG, Yolken RH. Deciphering microbiome and neuroactive immune gene interactions in schizophrenia. Neurobiol Dis. 2018; Available from: https://www.ncbi.nlm.nih.gov/pubmed/30471416.
8. Mahmodpoor F, Saadat YR, Barzegari A, Ardalan M, Vahed SZ. The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother. 2017;92:412–9.
9. Nagraj R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome Dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res. 2018;2018:3462092.
10. Jang SE, Lim SM, Jeong JJ, Jang HM, Lee HJ, Han MJ, et al. Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice. Microb Immunol. 2018;1:369–79.
11. Jalanka-Tuovinen J, Saloljärvi J, Salonen A, Immonen O, Garsed O, Kelly FM, et al. Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014; Cited 2019 Jun 20. Available from: https://gut.bmj.com/content/63/11/1737.long
12. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015;61:883–94.
13. Hu J, Luo H, Wang J, Tang W, Lu J, Wu S, et al. Enteric dysbiotic-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice. Exp Mol Med. 2017;49:e370.
14. Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol. 2018;136:345–61.
15. Huang R, Wang K, Hu J. Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016 Available from: https://www.ncbi.nlm.nih.gov/pubmed/27590521.
16. Ng OX, Peters C, Ho CYK, Lim DY, Yeo WS. A meta-analysis of the use of probiotics to alleviate depressive symptoms. J Affect Disord. 2018;228:13–9.
17. Liang S, Wu X, Hu X, Wang T, Jin F. Recognizing depression from the microbiota–gut–brain axis. Int J Mol Sci. 2018;19:15520.
18. Dinan TG, Cryan JF. Melanin-concentrating hormone: a link between gut microbiota and depression? Neurogastroenterol Motil. 2013;25:713–9.
19. Hu R, Zeng B, Zeng L, Cheng K, Li B, Luo Y, et al. Microbiota modulate anxiety-like behavior and endocrine abnormalities in hypothalamic-pituitary-adrenal axis. Front Cell Infect Microbiol. 2017;7:849.
20. Zingone F, Swift GL, Card TR, Sanders DS, Ludvigsson JF, Bai JC. Psychological morbidity of celiac disease: a review of the literature. United European Gastroenterol J. 2015;3:136–45.
21. Fasano A. Celiac Disease, Gut-Brain Axis, and Behavior: Cause, Consequence, or Merely Epiphenomenon? Pediatrics. 2017;139:e20164323.
22. Sander GR, Cummigs AG, Henshall T, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett. 2005;579:4851–5.
23. Vazquez-Roque ML, Camilleri M, Smyth T, Murray JA, Marietta E, O'Neill J, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144:903–911.e3.
34. Gutiérrez S, Pérez-Ándres J, Martínez-Blanco H, Ferrero MA, Vaqueró L, Vivas S, et al. The human digestive tract has proteases capable of gluten hydrolysis. Mol Med. 2016;7:693–702.
35. Busby E, Bold J, Fellows L, Rostami K. Mood disorders and gluten: it’s not all in your mind: a systematic review with meta-analysis. Nutrients. 2018;10(7):808.
36. Rudzki L, Pawlik D, Pawlik K, Waszkiewicz N, Malus A, Konieczewska B, et al. Immune suppression of IgG response against dairy proteins in major depression. BMC Psychiatry. 2017;17:268.
37. Lebwohl B, Cao Y, Zong G, Hu FB, Green PRR, Neugut AI, et al. Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study. BMJ. 2017;357:j1892.
38. Rivière A, Moens F, Selak M, Maes D, Wecks S, De Vuyst L. The ability of Bifidobacteria to degrade Arabinoxylan oligosaccharide constituents and derived oligosaccharides is strain dependent. Appl Environ Microbiol. 2014;80:204–17.
39. Bordoni A, Danesi F, Dardevet D, Dupont D, Fernandez AS, Gille D, et al. Dairy products and inflammation: a review of the clinical evidence. Crit Rev Food Sci Nutr. 2017;57:2497–525.
40. Sarkar A, Lehto SM, Harry S, Dinan TG, Cryan JF, Burnet PWJ. Psychobiotics and the manipulation of bacteria–gut–brain signals. Trends Neurosci. 2016;39:367–83.
41. Messaoudi M, Volle N, Bisson J-F, Desor D, Javelot H, Rougeot C. Beneficial psychiological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2:256–61.
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Washington: American Psychiatric Pub; 2013.
43. Pludowski P, Holick MF, Grant WB, Konstantynowicz J, Mascarenhas MR, Haq A, et al. Vitamin D supplementation guidelines. J Steroid Biochem Mol Biol. 2018;185:125–35.
44. Urbaniak GC, Plos S. Research Randomizer (Version 4.0). Retrieved on June 22, 2013, 2013.
45. Lidia Wadowolska. Cited 2019 Mar 18. Available from: http://www.uwm.edu.pl/edu/LidiaWadowolska/
46. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381–95.
47. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
48. Beck AT. Depression: clinical, experimental, and theoretical aspects. Philadelphia: University of Pennsylvania Press; 1967.
49. Derogatis LR, Lipman RS, Covi I. The SCL-90: an outpatient psychiatric rating scale. Psychopharmacol Bull. 1973;9:13.
50. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Philadelphia: University of Pennsylvania Press; 1992.
51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Washington: American Psychiatric Pub; 2013.
52. Akapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563–9.
53. Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Humphreys A, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2016;65:1913–20.
54. Xiao R, Wu BG, Goldklang M, McClelland M, Segal LN, D‘Aimmento JM. Cigarette smoke dysregulates gut microbiome in multiple strains of mice correlating with inflammation in the lung. A13 role of dysbiosis in lung disease. Am Thorac Soc. 2017;19:5A1006.
55. Tlobakuu M, Kamimura D, Kianouch S, DeFilippis AP, Al Rifai M, Reynolds LM, et al. The association between cigarette smoking and inflammation: the genetic epidemiology network of Atherosclerosis (GENOA) study. PLoS One. 2017;12:e0184914.
56. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. 2011;
57. Aye IL, Lager S, Ramirez V, Gaccioli F, Dudley DJ, Jansson T, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placential inflammatory pathways. Biol Reprod. 2014;90:129.
58. Guárdia M, Solà R, Vallvé JC, Gróna J, Godas G, Heras M, et al. Body mass index correlates with atherogenic lipid profile even in nonobese, normoglycemic, and normolipidemic healthy men. J Clin Lipidol. 2015;9:824–831.e1.
59. Yang XY, Shao MJ, Zhou Q, Xia Y, Zou HQ. Association of waist-to-hip ratio with insulin resistance in non-diabetic-normal-weight individuals: a cross-sectional study. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:1540–4.
60. Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566–75.
61. Jasper HH. The ten-twenty electrode system of the international federation. Electroencephalogr Clin Neurophysiol. 1958;10:370–5.
62. Sreek M, Koessler L, Bast T, Leijten FJ, Michel C, Baumgartner C, et al. The standardized EEG electrode array of the FCN. Clin Neurophysiol. 2017;128:2070–7.
63. Stream C, Neile G, Daffertshofer A. Phase lag index: assessment of functional connectivity from multi channel EEG and MEG with diminished bias from common sources. Hum Brain Mapp. 2007;28:1178–93.
64. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186.
65. Tewarie P, van Delen E, Hillebrand A, Stam CJ. The minimum spanning tree: an unbiased method for brain network analysis. Neuroimage. 2015;104:177–88.
66. Lee TW, Wu Y-T, Yu YWY, Chen M-C, Chen T-J. The implication of functional connectivity strength in predicting treatment response of major depressive disorder: a resting EEG study. Psychiatry Res Neuroimaging. 2011;194:372–7.
67. Olbrich S, Ams M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int Rev Psychiatry. 2013;25:604–18.
68. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:7537–41.
69. Qust C, Pruess E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2012;41:D590–6.
70. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814.
71. What is Physiological Measurement? Cited 2019 Mar 18. Available from http://www.bscn.org.uk/data/files/links/what-is-physiological-measurement.pdf
72. Food and Drug A. Guidance for industry: E9 statistical principles for clinical trials. Rockville: Food and Drug Administration; 1998.
73. The Comprehensive R Archive Network. Cited 2019 Mar 18. Available from: http://cran.r-project.org/
74. Barnes D, Varghese C, Hickey P, O’Neill AC. The implication of functional connectivity between resting state networks and memory function in schizophrenia. Schizophr Res. 2018;201:230–5.
75. Ferrer A, Aleman A, Alafuzoff I, Pujol J. The minimum spanning tree: a common source of bias in resting state functional connectivity. Brain Topogr. 2015;28:348–54.
76. Schlagl E, Havinga MR, Bulten WJ, van Os J, van der Flier WM, Meijer H, et al. Diminished intrinsic functional connectivity is associated with reduced memory function in patients with major depressive disorder. Hum Brain Mapp. 2016;37:1545–53.
77. Schlagl E, Havinga MR, Bulten WJ, van Os J, van der Flier WM, Meijer H, et al. Diminished intrinsic functional connectivity is associated with reduced memory function in patients with major depressive disorder. Hum Brain Mapp. 2016;37:1545–53.
78. Schlagl E, Havinga MR, Bulten WJ, van Os J, van der Flier WM, Meijer H, et al. Diminished intrinsic functional connectivity is associated with reduced memory function in patients with major depressive disorder. Hum Brain Mapp. 2016;37:1545–53.
79. Schlagl E, Havinga MR, Bulten WJ, van Os J, van der Flier WM, Meijer H, et al. Diminished intrinsic functional connectivity is associated with reduced memory function in patients with major depressive disorder. Hum Brain Mapp. 2016;37:1545–53.
85. Bonder MJ, Tiggelaar EF, Cai X, Trynka G, Cenit MC, Hrdlickova B, et al. The influence of a short-term gluten-free diet on the human gut microbiome. Genome Med. 2016;8:45.
86. Mohan M, Chow CT, Ryan CN, Chan LS, Dufour J, Aye PP, et al. Dietary gluten-induced gut Dysbiosis is accompanied by selective upregulation of microRNAs with intestinal tight junction and Bacteria-binding motifs in rhesus macaque model of celiac disease. Nutrients. 2016;8 Available from: https://www.ncbi.nlm.nih.gov/pubmed/27801835.
87. Phromraksa P, Nagano H, Boonmars T, Kamboonruang C. Identification of proteolytic bacteria from thai traditional fermented foods and their allergenic reducing potentials. J Food Sci. 2008;73:M189–95.
88. Caminero A, Nistal E, Herrán AR, Pérez-Andrés J, Vaquero L, Vivas S, et al. Gluten metabolism in humans: involvement of the gut microbiota. Wheat and Rice in Disease Prevention and Health. Maryland: Elsevier; 2014. p. 157–70.
89. Caminero A, Meisel M, Jabri B, Verdu EF. Mechanisms by which gut microorganisms influence food sensitivities. Nat Rev Gastroenterol Hepatol. 2019;16:7–18.
90. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. Nat Rev Gastroenterol Hepatol. 2015;12:497–506.
91. Garcia-Mazcorro JF, Rivera-Gutierrez X, Cobos-Quevedo OJ, Grube-Pagola P, Meixueiro-Daza A, Hernandez-Flores K, et al. First insights into the gut microbiota of Mexican patients with celiac disease and non-celiac gluten sensitivity. Nutrients. 2018;10 Available from: https://www.ncbi.nlm.nih.gov/pubmed/30400238.
92. Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue barriers. 2016;4:e1251384.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.